Skip to main content

Table 2 Summary of the significant parameters for different malignant grades and molecular subtypes

From: Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization

 

Emax (kPa)

fmass (Hz)

Dmax (mm)

NV

mvFD

NB

Histologic type

 Benign (310)

      

Fibroadenoma (109)

49.5 ± 33.8

143.0 ± 64.5

448.6 ± 262.8

5.9 ± 9.8

0.92 ± 0.43

2.8 ± 6.2

 Benign changes (77)

44.5 ± 38.6

146.4 ± 94.0

356.9 ± 291.6

2.9 ± 5.4

0.83 ± 0.38

1.2 ± 2.6

 Fibrocystic changes (30)

48.6 ± 31.9

171.1 ± 104.4

429.3 ± 282.6

4.4 ± 7.9

0.87 ± 0.43

1.7 ± 4.0

 Papilloma (28)

51.8 ± 39.2

186.7 ± 88.3

454.0 ± 273.3

3.4 ± 4.2

0.95 ± 0.28

1.3 ± 1.8

 PASH (22)

36.3 ± 28.3

139.8 ± 79.6

438.7 ± 247.5

3.1 ± 3.8

0.95 ± 0.27

1.0 ± 1.6

 Fat necrosis (18)

97.1 ± 70.6

203.5 ± 184.1

574.9 ± 106.2

3.9 ± 3.0

1.1 ± 0.11

1.5 ± 1.3

 Atypical (14)

51.2 ± 34.3

192.3 ± 105.3

303.4 ± 305.7

5.1 ± 9.9

0.75 ± 0.48

2.7 ± 5.6

 Duct ectasia (6)

45.9 ± 20.7

231.8 ± 86.7

501.0 ± 270.8

2.5 ± 2.1

0.95 ± 0.19

0.5 ± 0.5

 Adenoma (4)

47.9 ± 29.1

99.2 ± 56.2

655.4 ± 165.2

22 ± 22.7

1.28 ± 0.23

10.5 ± 13.0

 Others (2)

103.0 ± 95.8

243.9 ± 71.1

708.5 ± 238.7

10 ± 11.3

1.24 ± 0.25

7 ± 8.5

 p valuea

.03

.02

.03

.003

.01

.06

Malignant (204)

 IDC (136)

161.6 ± 65.1

212.3 ± 124.9

640.9 ± 197.3

15.2 ± 15.9

1.19 ± 0.21

7.4 ± 9.2

 IMC with mixed ductal and lobular features (27)

174.7 ± 68.3

227.8 ± 139.1

593.0 ± 278.2

17.0 ± 18.4

1.16 ± 0.23

8.2 ± 10.1

 ILC (24)

168.8 ± 56.2

241.1 ± 128.9

567.6 ± 268.8

14.6 ± 25.0

1.14 ± 0.19

7.3 ± 14.6

 DCIS (15)

94.6 ± 74.5

253.3 ± 172.6

503.8 ± 291.7

7.3 ± 5.9

1.11 ± 0.23

3.7 ± 3.4

 Other (2)

154.1 ± 48.5

97.2 ± 90.6

811.4 ± 142.3

100 ± 76.4

1.50 ± 0.13

69 ± 46.7

 p valuea

.55

.48

.22

.33

.21

.31

Histologic grade

 I (54)

139.1 ± 69.2

278.5 ± 117.1

553.6 ± 244.3

7.5 ± 8.3

1.10 ± 0.20

3.5 ± 4.4

 II (92)

168.0 ± 66.0

220.6 ± 140.7

617.7 ± 210.2

15.0 ± 16.3

1.18 ± 0.18

7.3 ± 9.2

 III (54)

165.8 ± 64.2

155.6 ± 90.8

673.9 ± 233.5

24.1 ± 28.6

1.24 ± 0.24

12.4 ± 18.3

 p valuea

.05

 < .001

.02

 < .001

 < .001

 < .001

Molecular subtypes

 Luminal A (76)

155.7 ± 66.4

257.3 ± 120.5

577.0 ± 241.4

10.8 ± 14.2

1.13 ± 0.21

5.2 ± 8.0

 Luminal B (HER2-) (58)

176.4 ± 61.4

218.2 ± 139.0

625.5 ± 181.0

15.2 ± 15.7

1.18 ± 0.16

7.4 ± 9.3

 Luminal B (HER2 +) (21)

198.4 ± 49.8

136.2 ± 98.4

727.1 ± 155.5

28.6 ± 32.6

1.30 ± 0.13

14.5 ± 21.8

 HER2 + (4)

169.1 ± 31.5

95.5 ± 33.2

628.7 ± 149.6

15.8 ± 14.5

1.20 ± 0.18

7.3 ± 6.4

 TNBC (20)

131.6 ± 65.4

189.3 ± 85.6

543.2 ± 311.5

13.9 ± 16.3

1.11 ± 0.35

7.3 ± 10.8

 p valuea

.005

 < .001

.07

.002

.01

.02

  1. Numbers are mean ± standard deviation, numbers in parentheses are numbers of participants
  2. DCIS, ductal carcinoma in situ. IDC, invasive ductal carcinoma. ILC, invasive lobular carcinoma. IMC with mixed ductal and lobular features, invasive mammary carcinoma with mixed ductal and lobular features. PASH, pseudoangiomatous stromal hyperplasia. TNBC, triple negative breast cancer
  3. aKruskal-Wallis test